A5038333200- Prostate Cancer Treatment and Research
- Radiopharmaceutical Chemistry and Applications
- PARP inhibition in cancer therapy
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Testicular diseases and treatments
- Cancer, Lipids, and Metabolism
- Bladder and Urothelial Cancer Treatments
- Prostate Cancer Diagnosis and Treatment
- Sarcoma Diagnosis and Treatment
- Venous Thromboembolism Diagnosis and Management
- Inflammatory Biomarkers in Disease Prognosis
- Cancer Treatment and Pharmacology
- Multiple Myeloma Research and Treatments
- Renal cell carcinoma treatment
- Urinary and Genital Oncology Studies
- Urologic and reproductive health conditions
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
- Cancer, Hypoxia, and Metabolism
- Neutropenia and Cancer Infections
- Bone health and treatments
- Cancer Cells and Metastasis
- Lymphoma Diagnosis and Treatment
- Cancer Diagnosis and Treatment
Hospital Universitario 12 De Octubre
2003-2024
Hospital General Universitario Morales Meseguer
2014-2024
Universidad Católica San Antonio de Murcia
2016-2024
Research Institute Hospital 12 de Octubre
2004-2024
Universidad de Murcia
2013-2024
Universidad Complutense de Madrid
2024
Centro Regional de Hemodonación
2015-2019
Instituto Murciano de Investigación Biosanitaria
2018-2019
Beth Israel Deaconess Medical Center
2013-2018
Spanish National Cancer Research Centre
2017
Germline mutations in DNA damage repair (DDR) genes are identified a significant proportion of patients with metastatic prostate cancer, but the clinical implications these remain unclear. This prospective multicenter cohort study evaluated prevalence and effect germline DDR (gDDR) on castration-resistance cancer (mCRPC) outcomes.Unselected were enrolled at diagnosis mCRPC screened for gDDR 107 genes. The primary aim was to assess impact ATM/BRCA1/BRCA2/ PALB2 cause-specific survival (CSS)...
BackgroundThere is an urgent need to identify biomarkers guide personalized therapy in castration-resistant prostate cancer (CRPC). We aimed clinically qualify androgen receptor (AR) gene status measurement plasma DNA using multiplex droplet digital PCR (ddPCR) pre- and post-chemotherapy CRPC.MethodsWe optimized ddPCR assays for AR copy number mutations retrospectively analyzed from patients recruited one of the three biomarker protocols with prospectively collected clinical data. evaluated...
Tumor microenvironment immunity is associated with breast cancer outcome. A high lymphocytic infiltration has been response to neoadjuvant chemotherapy, but the contribution and prognosis of immune cell subpopulations profiles in both pre-treated post-treatment residual tumor still unclear.We analyzed pre- tumor-infiltrating cells (CD3, CD4, CD8, CD20, CD68, Foxp3) by immunohistochemistry a series 121 patients homogeneously treated chemotherapy. Immune were correlated survival.We identified...
The classification of the International Germ-Cell Cancer Collaborative Group (IGCCCG) has been a major advance in management germ-cell tumors, but relies on data only 660 patients with seminoma treated between 1975 and 1990. We re-evaluated this database from large international consortium.Data 2,451 men metastatic cisplatin- etoposide-based first-line chemotherapy 1990 2013 were collected 30 institutions or collaborative groups Australia, Europe, North America. Clinical trial registry...
UBE2O is localized in the 17q25 locus, which known to be amplified human cancers, but its role tumorigenesis remains undefined. Here we show that Ube2o deletion MMTV-PyVT or TRAMP mice profoundly impairs tumor initiation, growth, and metastasis, while switching off metabolic reprogramming of cells. Mechanistically, specifically targets AMPKα2 for ubiquitination degradation, thereby promotes activation mTOR-HIF1α pathway. Notably, inactivation AMPKα2, not AMPKα1, abrogates attenuation caused...
Tumor DNA circulates in the plasma of cancer patients admixed with from noncancerous cells. The genomic landscape has been characterized metastatic castration-resistant prostate (mCRPC) but methylome not extensively explored. Here, we performed next-generation sequencing (NGS) on and without bisulfite treatment mCRPC receiving either abiraterone or enzalutamide pre- post-chemotherapy setting. Principal component analysis indicated that main contributor to methylation variance (principal one,...
Prostate cancer is the most prevalent in males, and treatment options are limited for advanced forms of disease. Loss PTEN TP53 tumor suppressor genes commonly observed prostate cancer, whereas their compound loss often cancer. Here, we show that PARP inhibition triggers a p53-dependent cellular senescence PTEN-deficient setting prostate. Surprisingly, also find PARP-induced morphed into an apoptotic response upon p53. We further superactivation prosurvival PI3K-AKT signaling pathway limits...
PTEN is a lipid phosphatase that antagonizes the PI3K/AKT pathway and recognized as major dose-dependent tumor suppressor. The cellular mechanisms control levels therefore offer potential routes to therapy, but these are yet poorly defined. Here we demonstrate plays an unexpected role in regulating its own stability through transcriptional upregulation of deubiquitinase USP11 by PI3K/FOXO pathway, further show this feedforward mechanism implicated tumor-suppressive role, mice lacking Usp11...
Angiogenesis is a key process for tumor progression and target treatment. However, the regulation of breast cancer angiogenesis its relevance clinical resistance to antiangiogenic drugs still incompletely understood. Recent developments on contribution microRNA oncogenic effects miR-17-92, miRNA cluster, point their potential role angiogenesis. The aim this work was establish miR-20a, member miR-17-92 in patients with invasive carcinoma.Tube-formation vitro assays conditioned medium from...
BackgroundAndrogen deprivation therapy (ADT) with docetaxel (D) and/or antiandrogen receptor therapies (ARTs) are the standard in metastatic hormone-sensitive prostate cancer (mHSPC). Alterations tumor suppressor genes (TSGs) RB1, PTEN, and TP53 associated an aggressive evolution treatment resistance castration-resistant (CRPC).ObjectiveTo study clinical implications of TSG mRNA expression mHSPC patients.Design, setting, participantsThis is a multicenter retrospective biomarker patients....
Predictive models to identify low-risk febrile neutropenia (FN) have been developed with heterogeneous samples, which included stable and unstable patients, solid tumours, acute leukaemia bone marrow transplantation. These fail recognise 5–15% of cases unexpected complications, literature specifically addressing apparently patients (ASPs) is scarce. We reviewed 861 episodes FN in outpatients including 692 (80%) apparent clinical stability. aimed investigate the prognosis this latter group...
Peripheral blood lymphocyte (PBL) count may reflect the immune status of cancer patients. We retrospectively analyzed predictive and prognostic impact baseline post-chemotherapy PBL counts in a homogeneous group 103 breast patients treated with neoadjuvant chemotherapy (anthracyclines taxanes). In univariate analysis, under 1500 × 106/L (p = 0.013; hazard ratio [HR]: 2.80, 95%CI 1.24–6.61), decrease >200 after first cycle 0.047; HR: 2.82, 1.01–7.86) were significantly related to disease free...
11506 Background: Dedifferentiated chondrosarcoma (DDCS) is a rare aggressive CS subtype with dismal prognosis and no standard of care systemic therapy. For those advanced, metastatic disease, retrospective chemotherapy studies demonstrate short-term median progression-free survival (PFS) around 3 to 5.5 months. Benefit from checkpoint tyrosine kinase inhibitors has been reported, however clinical trial data scarce, endpoints are not well defined, thus benchmarking outcomes challenging. The...
Many studies have investigated symptoms, comorbidities, demographic factors, and vaccine effects in relation to long COVID (LC-19) across global populations. However, a number of these shortcomings, such as inadequate LC-19 categorisation, lack sex disaggregation, or narrow focus on certain risk factors like symptoms comorbidities alone. We address gaps by investigating the present during acute phase primary COVID-19 infection among patients with comparing them typical non-Long patients....
Abstract BACKGROUND Cancer patients with fever and neutropenia currently are assessed on clinical grounds only. The current study prospectively evaluated the efficacy of baseline procalcitonin (PCT) in detection bacteremia prediction outcome solid tumors febrile neutropenia. METHODS PCT levels were determined at every 48 hours 104 undergoing chemotherapy who developed (axillary temperature > 38 °C 2 occasions or 38.3 a single record) (absolute neutrophil count < 500 cells/μL). RESULTS...